2016年意大利临床内分泌学家学会骨质疏松的药物治疗立场声明解读  

Interpreting the Italian Association of Clinical Endocrinologists (AME) Position Statement:Drug Therapy of Osteoporosis

作　　者：金小岚[1] JIN Xiao-lan(Department of Endocrinology, Chengdu Military General Hospital, Chengdu Sichuan 610083, China)

机构地区：[1]成都军区总医院内分泌科,四川成都610083

出　　处：《药品评价》2017年第9期13-16,36,共5页Drug Evaluation

摘　　要：骨质疏松的治疗目的是防止脆性骨折的发生,稳定和增加骨密度。2016年3月,意大利内分泌学家学会在线发布的关于骨质疏松药物治疗的立场声明中,介绍了目前所有用于骨质疏松症治疗药物的疗效和安全性、长期治疗策略、药物调整、治疗疗程等。本文仅就这个立场声明的主体部分绝经后骨质疏松(postmenopausal osteoporosis,PMO)的药物治疗作一简要的解读,并与近年来骨质疏松领域的其他权威学术机构发布的指南进行适当比较。Treatment of osteoporosis is aimed to prevent fragility fractures and stabilize or increase bone mineral density.This statement introduces efficacy and safety profiles of several drugs,also including the long-term therapeutic strategy,alternative therapy and its duration.This article only interprets the part related to the drug treatment for the postmenopausal osteoporosis,and compared it with other authoritative academic institutions in recent years.

关 键 词：绝经后骨质疏松 AME 立场声明 解读 

分 类 号：R580[医药卫生—内分泌]